Correction of mineral and bone disorders in a patient with long-standing diabetes mellitus type 1 on hemodialysis therapy
https://doi.org/10.14341/omet2016248-55
Abstract
Osteoporosis and diabetes mellitus (DM) – chronic diseases with constantly growing prevalence. Patients with DM have the increased risk of bones fractures. Risk of fracture in the patient with diabetes mellitus type 1 (DM1) is increased by more than 6 times. There are several mechanisms leading to the development of osteoporosis in DM: chronic hyperglycemia, insulin deficiency, genetic factors, and complications of DM. Moreover, the chronic kidney disease in DM impacts not only progression of osteoporosis, but also leads to emergence of other bone disorders, that considerably complicate a choice of antiosteoporotic treatment. This article describes a clinical case of the mineral and bone disorders of a phosphorus-calcium metabolism, which developed in patient with long history of DM1 receiving therapy by a program hemodialysis.
About the Authors
Igor A. Sklyanik
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
Daria N. Egorova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
Larisa K. Dzeranova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
Ekaterina A. Pigarova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
References
1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007 Apr;18(4):427–44. doi: 10.1007/s00198-006-0253-4
2. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in Patients With Diabetes Mellitus. J Bone Miner Res. 2007;22(9):1317–28. doi: 10.1359/jbmr.070510
3. Земченков АЮ, Герасимчук РП. Сосудистая кальцификация и активаторы рецепторов витамина D. Обзор литературы.// Нефрология и диализ. – 2009. – T. 11. №. 4. – С. 276–92. [Zemchenkov AYu, Gerasimchuk RP. Sosudistaya kal'tsifikatsiya i aktivatory retseptorov vitamina D. Obzor literatury. Nefrologiya i dializ. 2009;11(4):276–92. (In Russ).]
4. Мельниченко ГА, Марова ЕИ, Дзеранова ЛК, Вакс ВВ. Гиперпролактинемия у женщин и мужчин. Пособие для врачей. Москва; 2007. [Mel'nichenko GA, Marova EI, Dzeranova LK, Vaks VV. Giperprolaktinemiya u zhenshchin i muzhchin. Posobie dlya vrachey. Moscow; 2007. (In Russ).].
5. Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Cimińska M, et al. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol. 2012;59(4):507-513.
6. Nyman JS, Even JL, Jo C-H, Herbert EG, Murry MR, Cockrell GE, et al. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone. 2011;48(4):733–40. doi: 10.1016/j.bone.2010.12.016
7. Poundarik AA, Wu P-C, Evis Z, Sroga GE, Ural A, Rubin M, et al. A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater. 2015;50:82–92. doi: 10.1016/j.jmbbm.2015.05.025
8. Рожинская Л.Я., Егшатян Л.В. Патология костной системы при вторичном гиперпаратиреозе у пациентов с терминальной стадией хронической болезни почек на заместительной почечной терапии (гемодиализ)(обзор литературы) // Остеопороз и остеопатии. – 2010. – T. 6. – №. 2. – C. 18-22. [Rozhinskaya LYa, Eglatyan LV. Patologiya kostnoy sistemy pri vtorichnom giperparatireoze u patsientov s terminal'noy stadiey khronicheskoy bolezni pochek na zamestitel'noy pochechnoy terapii (gemodializ) (obzor literatury). Osteoporoz i osteopatii. 2010;6(2):18–22. (In Russ).]
9. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 2006;69(11):1945–53. doi: 10.1038/sj.ki.5000414
10. Борисов А.В., Ильина А.Н., Рожинская Л.Я., и др. Паратиреоидная функция и минеральная плотность костной ткани у пациентов с хронической почечной недостаточностью, находящихся на лечении программным гемодиализом // Остеопороз и остеопатии. – 2004. – Т. 1. – С. 6-10.[Borisov AI, Mordik AI, Borisova EV, Ermakova IP, Il'ina AN, Rozhinskaya LYa, et al. Paratireoidnaya funktsiya i mineral'naya plotnost' kostnoy tkani u patsientov s khronicheskoy pochechnoy nedostatochnost'yu, nakhodyashchikhsya na lechenii programmnym gemodializom. Osteoporoz i osteopatii. 2004;1:6–10. (In Russ).]
11. Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–9. doi: 10.1038/sj.ki.5000414
12. Chen CL, Chen NC, Hsu CY, et al. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99(7):2426–32. doi: 10.1210/jc.2014-1154
13. Dusilova Sulkova S, Horacek J, Safranek R, et al. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature. Acta Medica (Hradec Kralove). 2014;57(1):30–3. doi: 10.14712/18059694.2014.6
Review
For citations:
Sklyanik I.A., Egorova D.N., Dzeranova L.K., Pigarova E.A. Correction of mineral and bone disorders in a patient with long-standing diabetes mellitus type 1 on hemodialysis therapy. Obesity and metabolism. 2016;13(2):48-55. (In Russ.) https://doi.org/10.14341/omet2016248-55
Views:
2388
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
